Posted by Michael Wonder on 04 Apr 2023
Koselugo approved in Canada for paediatric patients with neurofibromatosis type 1 plexiform neurofibromas
3 April 2023 - First and only therapy approved to treat this rare and debilitating genetic condition.
Alexion, AstraZeneca Rare Disease today announced that Health Canada has granted a Notice of Compliance for Koselugo (selumetinib) for the treatment of paediatric patients aged two years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
